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Abstract
Background: Collecting duct carcinoma (CDC) is a rare but very aggressive variant of kidney
carcinoma that arises from the epithelium of Bellini's ducts, in the distal portion of the nephron. In
order to gain an insight into the biology of this tumor we evaluated the expression of five genes
involved in the development of renal cancer (FEZ1/LZTS1, FHIT, TP53, P27kip1, and BCL2).
Methods: We studied eleven patients who underwent radical nephrectomy for primary CDC. All
patients had an adequate clinical follow-up and none of them received any systemic therapy before
surgery. The expression of the five markers for tumor initiation and/or progression were assessed
by immunohistochemistry and correlated to the clinicopathological parameters, and survival by
univariate analysis.
Results: Results showed that Fez1 protein expression was undetectable or substantially reduced
in 7 of the 11 (64%) cases. Fhit protein was absent in three cases (27%). The overexpression of p53
protein was predominantly nuclear and detected in 4 of 11 cases (36%). Immunostaining for p27
was absent in 5 of 11 cases (45.5%). Five of the six remaining cases (90%) showed exclusively
cytoplasmic protein expression, where, in the last case, p27 protein was detected in both nucleus
and cytoplasm. Bcl2 expression with 100% of the tumor cells positive was observed in 4 of 11 (36%)
cases. Statistical analysis showed a statistical trend (P = 0.06) between loss and reduction of Fez1
and presence of lymph node metastases.
Conclusions: These findings suggest that Fez1 may represent not only a molecular diagnostic
marker but also a prognostic marker in CDC.
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Background
Renal cancer accounts for 3% of adult malignancies. An
estimated 35,710 new cases are expected to occur in the
U.S. in the current year and 12,480 patients will die of this
disease [1]. The majority of renal cancers arises from the
proximal tubular epithelium, with a characteristic clear or
granular cell appearance by light microscopy, and is
referred to as renal cell carcinoma (RCC).
Recent evidence suggests that solid renal parenchymal
tumors arising in the distal portion of the nephron, such
as oncocytomas, chromophobe renal cell carcinomas and
collecting duct carcinomas represent an heterogeneous
group of neoplasm from both clinical and biological per-
spectives [2]. Collecting duct carcinoma (CDC), also
known as Bellini duct carcinoma, is a rare but highly
aggressive renal neoplasm arising from the distal portion
of the nephron, and represents approximately 2% of all
the RCCs [3,4]. Clinically, CDC appears as a renal mass
often accompanied by flank pain and hematuria and is
frequently mistaken for RCC or transitional cell carci-
noma of the renal pelvis [3,5,6]. CDC, however, can be
identified based on gross, microscopic, histochemical,
and immunohistochemical features. Macroscopically,
CDCs are often located at the confluence of the medulla
and renal pelvis, and show a characteristic gray-white-tan
color, with absence of foci of necrosis and hemorrhage
[7]. Histologically, CDC presents a tubulo-papillary mor-
phology, often accompanied by desmoplasia, atypia in
collecting ducts, and intratubular spread [7], features
rarely seen in RCC.
Histochemically, CDC cells contain intracytoplasmic
mucicarminophilic material, where RCCs do not [7].
CDCs are also positive by immunohistochemical staining
with high-molecular-weight keratin and lectin, proteins
typically expressed in the epithelium of the distal tubules
[8,9]. Conversely, almost all other renal carcinomas
express antigens widely expressed in the cells of the prox-
imal tubules, such as low molecular weight cytokeratins
and vimentin [9]. Although little is known about the
genetic profile of CDCs, a DNA flow cytometry study has
demonstrated aneuploidy in 90% of these tumors [5], and
cytogenetics has shown frequent monosomy of chromo-
somes 1, 6, 8, 14, 15, and 22 [10,11].
Loss of heterozygosity (LOH) analysis in six CDCs
revealed allelic loss at chromosomes 8p and 13q in 50%
of the tumors, and rarely at the short arm of chromosome
3 [12,13]. This data suggests that distinct genetic altera-
tions from those observed in RCC, in which 3p LOH is
common [14], occur in the development of this rare renal
tumor.
To improve our understanding of the biology of CDC and
to explore the possibility that different genes may be
involved in the etiology and prognosis of this neoplasm,
we analyzed by immunohistochemistry eleven cases of
CDC for the expression of five genes (Fez1, Fhit, p53, p27,
and bcl2) often involved in the development of many
common cancers. These findings were correlated with
conventional clinical-pathological features including clin-
ical outcome.
Methods
Patients
Eleven patients with primary CDC (two women and nine
men; age range 40 to 84 years, mean 62) underwent radi-
cal nephrectomy between 1983 and 2000 in the Depart-
ment of Urology, University of Padua, Italy. Tissue
specimens from these tumors were registered in the
Department of Pathology at the same institution. All
eleven patients had an adequate clinical follow up and
were included in our study. Eight of the 11 patients had
metastatic disease, five with lymph node metastasis and
five with distant metastases at the time of surgery. None of
these eleven patients received any systemic therapy before
surgery. Samples were fixed in 10% buffered formalin for
routine histological processing and were stained with
hematoxylin and eosin.
Pathological study
Immunohistochemical reactions using anticytokeratin
(Keratins 5, 8, 10, an 18) monoclonal antibodies, and
Ulex Europaeus Lectin, polyclonal antibody were per-
formed as previously described [15]. The tumors were
classified histologically according to standardized criteria
[3,5-7] and staged according to the guidelines of the
tumor-node-metastasis (TNM) classification of malignant
tumor [16].
Immunohistochemistry
Paraffin sections containing non-neoplastic kidney as well
as neoplastic areas were deparaffinized according to
standard procedures followed by rehydration through
graded ethanol series, and mounted on positively charged
slides. Immunostaining was performed as previously
described [17]. Briefly for Fez1, Fhit, p53, and p27 immu-
nostaining, slides were immersed in citrate buffer [0.01 M
sodium citrate (pH6.0)] and heated in a microwave oven
at 600 W (three times for 5 min each) to enhance antigen
retrieval. For retrieval of Bcl2 oncoprotein, we used the
target retrieval solution, high pH from DAKO (Carpinte-
ria, CA, USA) per manufacturers instructions. The primary
antibodies used in this study were: anti-Fez1 rabbit poly-
clonal antibody [17], anti-Fhit rabbit polyclonal antibody
(Zymed Laboratories, San Francisco, CA) at 1:1,000 dilu-
tion, anti-p53, anti-p27, anti-Bcl2 (DAKO, Carpinteria,
CA, USA) at dilution of 1:25, 1:50, and 1:40 respectively,
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as specified by the manufacturers. The primary antibodies
were omitted and replaced with pre-immune serum in the
negative controls. Sections were reacted with biotinylated
anti-rabbit or anti mouse antibodies and streptavidin-
biotin-peroxidase (Histostain-SP Kit; Zymed laboratories,
San Francisco, CA). Diaminobenzidine (DAB) was used as
a chromogen substrate to visualize staining. Finally, sec-
tions were washed in distilled water and weakly counter-
stained with Harry's modified hematoxylin. The
immunostaining was evaluated by two pathologists in a
blinded fashion (A.V.; R.B.). For statistical analysis, cases
were scored as positive if they had more than 20% (p53)
or more than 40% (Fez1 and p27) of positive cells. Fhit
and bcl2 cases showed either all positive or all negative
cells and were scored accordingly.
Statistical analysis
We evaluated the association between each marker's
expression (positive or negative) and each clinical-patho-
logical outcome (metastasis and stage) with Fisher's exact
test. For survival, we used the Kaplan-Meier method and
log-rank test, as well as Cox proportional hazards
regression.
Results
Pathological study
All cases showed several common microscopic features.
The main tumor consisted of a tubulo-papillary carci-
noma showing pleomorphism and a high mitotic rate
with several bizarre mitotic figures, and presence of small
cystic spaces surrounded by a highly desmoplastic stroma.
Two cases showed a predominant papillary pattern
accompanied with dilated and atypical changes in the epi-
thelium of the collecting ducts in the adjacent renal
medulla, which was the most convincing feature support-
ing a collecting duct origin of these tumors. Metastases,
when available for examination, were histologically simi-
lar to the infiltrating part of the primary tumors. Immuno-
cytochemically, tumor cells from all cases examined did
not express keratin 10, while strong positivity to anti-ker-
atin 5, 8, and 18 antibodies, and anti-UEL antibody was
observed. The positivity to high molecular weight keratin
and UEL further substantiate the diagnosis of CDC. The
clinical-pathological features and protein expression of
the study's 11 cases are shown in Table 1.
Fez1 expression
Our results showed that Fez1 protein expression was
undetectable in six of the eleven (55%) cases. One case
showed a substantial reduction of expression with 60% of
the tumor cells negative, while the remaining four showed
diffuse positivity for Fez1 immunostaining (Figures 1A
and 1B). Overall 64% of the cases showed absence or
reduction of Fez1 expression. Loss and reduction of Fez1
were correlated with a higher prevalence of lymph node
metastases (71% vs. 0%, p = 0.061), although the same
was not true for distant metastases or tumor stage. Fez1-
negative tumors also tended to have higher mortality than
Fez1-positive tumors. Median survival time was estimated
to be 17 months for the former group, while median sur-
vival was not reached for the latter group during the
course of the study (i.e., fewer than half of the patients
died) (p = 0.078; Figure 2A). This corresponds to an
estimated 5-fold increase in mortality risk for the Fez1-
negative CDCs (hazard ratio of 5.5).
Table 1: Clinical-pathological features and protein expression.
PZ ID T N M STAGEa Fez1 Fhit P27 Bcl2 P53 Survival (months)
1 3 1 0 3 -* - - - +1 17+
2 4 2 0 4 - + - + - 8+
3 3 0 1 4 - - - - - 2+
4 4 2 1 4 - + Cyt - +2 35+
5 3 0 0 3 - + Cyt - +3 12+
6 3 1 1 4 - - - - - 18+
7 2 0 0 2 + + - - - 58#
8 3 0 0 3 + + Cyt + +4 55#
9 3 0 1 4 + + Cyt^ + - 8+
10 2 0 1 4 + + Cyt - - 16#
11 3 1 0 3 - + Cyt + - 7#
a staged following the guidelines of the tumor-node-metastasis (ref 16)
* Tumor showed 60% of the cells negative for Fez1 expression
^ Nuclear p27 was also detected in this case
1,2,3,4: Showed 85,20,30,50 % of the cells positive for p53 expression, respectively
+ Dead
#Alive
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Representative examples of immunohistochemical analysis of Fez1, Fhit, p53, p27 and bcl2 proteins in primary Bellini's duct car-cinoma of the kidneyFigure 1
Representative examples of immunohistochemical analysis of Fez1, Fhit, p53, p27 and bcl2 proteins in primary Bellini's duct car-
cinoma of the kidney. A, Normal renal parenchyma shows uniform, cytoplasmic positive staining for Fez1 (×400). B, Fez1 pro-
tein is absent in this CDC (Case 1; ×400). An adjacent dysplastic distal duct (red arrow) shows strong Fez1 immunoreacticity. C, 
CDC section showing diffuse cytoplasmic staining for Fhit protein (Case 2; ×400). D, CDC neoplastic glands display strong 
nuclear immunoreaction for p53 oncoprotein (Case 5; ×400). Case 9 shows p27 immunoreactivity in both nucleus and cyto-
plasm (E) and bcl2 cytoplasmic immunostaining, red arrow (F) (×400).
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Fhit expression
Fhit protein was absent in three of eleven cases (27%),
and the remaining eight showed diffuse immunoreactiv-
ity (Figure 1C). Reduction of Fhit protein expression did
not correlate with any of the clinicopathological features
of the tumors. There was a tendency for Fhit-negative cases
to have worse survival than Fhit-positive cases (median
survival times of 17 vs. 35 months, respectively; hazard
ratio of 2.7), although the difference was not statistically
significant (p = 0.206: Figure 2B).
p53 expression
p53 protein was found to be overexpressed mainly in the
nucleus in four of eleven cases (36%) (Figure 1D). One of
the four positive cases showed overexpression in 85% of
the cancer cells, whereas the remaining three showed
20%, 30% and 50% of positive cancer cells, respectively.
p53 was not detectable in seven of eleven cases (63%) as
well as in the normal renal epithelium adjacent to tumor.
Overexpression of p53 was not related to histologic grade,
tumor stage, lymph node status, and survival.
p27 expression
Immunoreactivity for p27 was observed in the nuclei of
most glomerular and tubular cells in the normal kidney.
p27 immunostaining in CDC showed high variability.
Protein expression was absent in five of eleven cases
(45.5%). All the remaining six carcinomas showed a high
percentage (> 40%) of p27 positive cells. The expression
of p27 protein was detected exclusively in the cytoplasm
in five of the six positive cases (90%) while a mixture of
nuclear and cytoplasmic protein staining was observed in
the last case (Figure 1E). Overall, we observed lack or sub-
cellular compartmentalization of p27 in 90% of the cases.
The status of p27 did not correlate to any of the clinical-
pathological parameters tested.
Bcl2 expression
Bcl2 protein expression in 100% of the CDC tumor cells
was observed in four of eleven cases (36%) (Figure 1F),
while the remaining seven (64%) were negative. Statistical
analysis did not reveal any significant correlation between
Bcl2 expression and other clinical-pathological
parameters.
Clinical-pathological features as well as immunohisto-
chemistry results are listed in Table 1. The proportion of
marker expression ranged from 36% (Fez1 and Bcl2) to
73% (Fhit). Marker expression tended to be positively cor-
related, with the correlation between Fhit and p27 being
the strongest (0.67), followed by that between Fhit and
Fez1 and Fhit and Bcl2 (both 0.46).
Discussion
The application of the most recent molecular cytogenetic
techniques revealed that renal parenchymal tumors can
be classified into distinct subtypes based on the
combination of specific genetic alterations [18]. The path-
ological and immunohistochemical description as well as
the cytogenetic abnormalities support the hypothesis that
Kaplan-Meier survival curves and associated log-rank test p-values for of eleven patients with collecting duct carcinoma of the kidney based on Fez1 (A), and Fhit (B) expressionFigure 2
Kaplan-Meier survival curves and associated log-rank test p-values for of eleven patients with collecting duct carcinoma of the 
kidney based on Fez1 (A), and Fhit (B) expression. (+); positive expression; (-) = negative expression; ■ and o = Event times.
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CDC is more similar to urothelial carcinoma than to clear
cell carcinoma of the kidney. Indeed, whereas allelic dele-
tion of the short arm of chromosome 3 is considered a
genetic hallmark of clear cell carcinoma, LOH at chromo-
somes 8p, 9p, and 17p has been frequently described in
both transitional cell carcinoma and CDC. Here, we have
reported the results of our immunohistochemical analysis
of the expression of five genes (FEZ1, FHIT, P53, P27kip1,
and BCL2) in a relatively large series of CDCs (eleven
cases), considering the rarity of this tumor.
FEZ1/LZTS1 (leucine zipper tumor suppressor 1) is a
putative tumor suppressor gene located at 8p22 [19].
Studies have indicated this chromosomal region is the
location of an important tumor suppressor gene (TSG)
[20]. LOH at 8p has been described in 50% of the CDCs
studied [12], suggesting that a TSG in this region may also
play a role in the development of this rare tumor. In our
study, we found loss of Fez1 expression in the majority of
CDCs studied and a correlation with the presence of
lymph node metastasis. Furthermore, lack of Fez1 protein
correlated with a poorer prognosis in 90% of patients with
median survival of 17 months.
FEZ1 encodes a 67-kDa leucine-zipper protein with a
region of similarity to cAMP-dependent activated protein
[19]. Mutations of FEZ1 gene have been reported in sev-
eral solid tumors, including prostate, breast, esophageal,
and gastric carcinomas [17,19]. In addition, reduced Fez1
expression is associated with high-grade transitional cell
carcinoma of the bladder [21]. Recent studies have shown
that the introduction of FEZ1 into Fez1 null cancer cells
reduced cell growth with the accumulation of cells at late
S to G2/M phase of the cell cycle. Conversely, inhibition of
Fez1 expression stimulated cells growth [22]. Further-
more, LOH at the chromosomal region where the FEZ1
gene lies (8p21-22) has been also associated with the
invasive behavior of breast cancer [23] and with prostate
cancer progression [24]. These data are consistent with an
important role of FEZ1 in several human cancers includ-
ing CDC.
The tumor suppressor gene FHIT maps to the short arm of
chromosome 3 (3p14.2), encompasses the common
FRA3B fragile region, and encodes for a protein of 16.8
kDa, with diadenosine triphosphate hydrolase activity
[25]. Reduction of Fhit protein expression as consequence
of alteration of the FHIT gene has been observed by
immunohistochemistry in many types of cancers [26,27].
Although Shoemberg et al. did not detect LOH involving
chromosome 3p [12], Hadaczek et al. reported LOH at 3p
in two cases of CDC [13]. The same authors described a
correlation between reduced Fhit expression and 3p allelic
loss in renal carcinomas, particularly in CDCs [28]. While
in our study Fhit inactivation does not seem to be a com-
mon event in CDC, an involvement of the FHIT gene in
tumorigenesis of this rare tumor cannot be excluded.
The TP53 tumor suppressor gene maps to chromosome
17p13.1 and plays a major role in DNA transcription, cell
growth, proliferation and apoptosis process [29]. In nor-
mal cells, expression of wild type p53 protein is generally
below the detection level when studied by immunohisto-
chemical method. However, p53 gene point mutations
occur frequently (22–76%) in different solid neoplasms.
Mutated p53 protein, being more resistant to degradation,
accumulates in the cells and can be detected by immuno-
histochemistry. Although an association between p53
protein overexpression and tumor stage, grade and sur-
vival has been observed in RCC [30] our data suggest that
involvement of p53 alterations does not occur with the
same frequency in CDC.
P27 is a member of the universal cyclin-dependent kinase
inhibitor (CDKI) family. The expression of this important
protein is regulated by cell to cell contact inhibition as
well as by specific growth factors, such as transforming
growth factor (TGF-β). In addition to its role as a CDKI,
p27 is considered a putative tumor suppressor gene, a
major regulator of drug resistance in solid tumors, and a
promoter of apoptosis. p27 acts also as a safeguard against
inflammatory injury and has a role in cell differentiation
[31]. It has been suggested that loss of the p27 negative
cell cycle regulation may contribute to oncogenesis and
tumor progression in several tumor types. In renal cell car-
cinoma, Kamai et al. reported that low level of p27 pro-
tein was associated with tumor invasion and unfavorable
prognosis, suggesting p27 as a powerful prognostic
marker for survival in urinary tract cancer [32]. Masuda et
al. indicated that p27 has an independent predictive prog-
nostic value for transitional cell carcinoma of the renal
pelvis [33]. Our results show that p27 loss or subcellular
compartmentalization represents a frequent feature in
CDCs. Previous studies have noted that cytoplasmic local-
ization of p27 lead to an inactivation of its normal func-
tion as negative cell cycle regulator [34].
Nevertheless, we did not find statistical correlation to
assess its involvement in CDC biology, possibly due to the
limited number of tumors studied.
The proto-oncogene BCL2, implicated in the regulation of
cell death by inhibiting apoptosis, seems to be vital in
normal kidney morphogenesis. In fact, Bcl2 deficient
mice develop polycystic kidneys characterized by dilated
proximal and distal tubules [35]. High levels of Bcl2 pro-
tein expression have been found in many different types
of cancer, suggesting a possible role for Bcl2 deregulation
of apoptosis and malignant tissue transformation. Expres-
sion of Bcl2 has also been associated with poor prognosis
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in patients with various cancers including prostate cancer
[36]. In the present study, Bcl2 expression was not associ-
ated with any clinical-pathological variables.
Our results suggest a potential association between FEZ1
expression and CDC pathology and prognosis. No similar
patterns were seen for any of the other markers studied.
Even so, the statistical power of the study was limited and
negative findings should not be construed as evidence
that these markers are not important. Rather, a larger
study would need to be carried out to further investigate
their role in CDC.
Conclusions
Our results suggest that Fez1 expression may be associated
to both clinical-pathological features and survival in
patients with CDC. FEZ1 gene alterations may be linked
to the high frequency of LOH found at 8p22, where FEZ1
resides. The lack of similar association for the other four
genes studied may be due to the low statistical power of
the study.
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